AdoRx Therapeutics Competitors and Similar CompaniesClear all

AdoRx Therapeutics's competitors and similar companies include S1 Biopharma, JCR Pharmaceuticals, Pulmotect and Kamada Pharmaceuticals.

	AdoRx Therapeutics AdoRx Therapeutics is a company that pursues the discovery of new therapeutics for cancer based on modulation of the adenosine pathway.	S1 Biopharma S1 Biopharma is a company developing drugs for the treatment of sexual dysfunction in both women and men.	JCR Pharmaceuticals JCR Pharmaceuticals is a company that specializes in the development of pharmaceutical products.	Pulmotect Pulmotect is a biopharmaceutical company providing products for patients at risk of respiratory diseases.	Kamada Pharmaceuticals Kamada Pharmaceuticals is a company that develops plasma-derived protein therapeutics for orphan indications.
Founding Date	Founding Date N/A	Founding Date 2008	Founding Date 1975	Founding Date 2007	Founding Date 1990
Type	Type Private	Type Private	Type Public	Type Private	Type Public
Tags	Tags Healthcare biotech drug development pharma therapy	Tags Healthcare biotech drug development pharma therapy	Tags Healthcare biotech drug development pharma therapy	Tags Healthcare biotech drug development pharma therapy	Tags Healthcare biotech drug development pharma therapy
Locations	Locations Edinburgh, GB HQ	Locations New York, US HQ	Locations Ashiya, JP HQ Kobe, JP Kobe, JP Kobe, JP Kobe, JP	Locations Houston, US HQ	Locations Rehovot, IL HQ Beit Kama, IL
Employees	Employees N/A	Employees 4	Employees 934	Employees 10	Employees 420
Valuation ($)	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 533.9 m	Valuation ($) N/A	Valuation ($) 317 m
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) ¥33.1b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) $180.5m (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods ¥8b (FY, 2025)	Cost of goods N/A	Cost of goods $72.1m (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit ¥25.1b (FY, 2025)	Gross profit N/A	Gross profit $108.4m (FY, 2025)
Net income	Net income N/A	Net income N/A	Net income (¥4.7b) (FY, 2025)	Net income N/A	Net income $20.2m (FY, 2025)
Funding
Latest funding round	Latest funding round $ 10m (almost 8 years ago)	Latest funding round N/A	Latest funding round N/A	Latest funding round $ 10.1m (about 8 years ago)	Latest funding round N/A
Total funding raised	Total funding raised $ 10m	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 11.9m	Total funding raised $ 90m